Naxozole (esomeprazole/naproxen) / Hanmi - LARVOL DELTA

LBP: A Study to Evaluate the Efficacy and Safety of HCP1004 in Chronic Low-Back Pain Patients (clinicaltrials.gov) - P3 | N=310 | Completed | Sponsor: Hanmi Pharmaceutical Company Limited | Recruiting ➔ Completed

Head-to-Head • Trial completion • Back Pain • Lumbar Back Pain • Musculoskeletal Pain • Pain

LBP: A Study to Evaluate the Efficacy and Safety of HCP1004 in Chronic Low-Back Pain Patients (clinicaltrials.gov) - P3 | N=286 | Recruiting | Sponsor: Hanmi Pharmaceutical Company Limited | Not yet recruiting ➔ Recruiting

Enrollment open • Head-to-Head • Back Pain • Lumbar Back Pain • Musculoskeletal Pain • Pain

LBP: A Study to Evaluate the Efficacy and Safety of HCP1004 in Chronic Low-Back Pain Patients (clinicaltrials.gov) - P3 | N=286 | Not yet recruiting | Sponsor: Hanmi Pharmaceutical Company Limited

Head-to-Head • New P3 trial • Back Pain • Lumbar Back Pain • Musculoskeletal Pain • Pain

Multivariate Assessment for Bioequivalence Based on the Correlation of Random Effect. (PubMed, Drug Des Devel Ther) - "Three pharmacokinetic datasets, fixed-dose combination (naproxen and esomeprazole), tramadol and fimasartan data were analyzed. This multivariate HGLM had good performance in the bioequivalence test with multiple endpoints. This method would provide a more reasonable option to reduce the 90% CI by adding correlation parameters and thus an advantage especially in evaluating the bioequivalence of highly variable drugs with broad 90% CIs."

Journal